Development and Clinical use of Prasugrel and Ticagrelor

By  

Current Pharmaceutical Design, Vol. 18, Iss. 33, 2012-11 ,pp. : 5240-5260

Bentham Science Publishers

Access to resources Recommend Favorite

Development of a membrane-targeted complement inhibitor for clinical use

By Dodd I.   Oldroyd R.G.   Powell S.   Affleck L.J.   Bamber L.   Gallagher S.   Rowling P.J.E.   Ragnauth C.   Smith G.P.   Pratt J.R.   Sacks S.H.   Linton S.M.   Morgan B.P.   Smith R.A.G.  

Immunopharmacology, Vol. 49, Iss. 1, 2000-08 ,pp. : 63-63

Elsevier

Access to resources Recommend Favorite

Whole body physiologically-based pharmacokinetic models: their use in clinical drug development

By Edginton Andrea N   Theil Frank-Peter   Schmitt Walter   Willmann Stefan  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 9, 2008-09 ,pp. : 1143-1152

Informa Healthcare

Access to resources Recommend Favorite

Biologic Aspects of Thrombopoietin and the Development of Novel Thrombopoietic Agents for Clinical Use

By  

Current Drug Discovery Technologies, Vol. 4, Iss. 3, 2007-10 ,pp. : 162-173

Bentham Science Publishers

Access to resources Recommend Favorite

Use of Pre-Clinical In Vitro and In Vivo Pharmacokinetics for the Selection of a Potent Hepatitis C Virus Protease Inhibitor, Boceprevir, for Clinical Development

By  

Letters in Drug Design & Discovery, Vol. 6, Iss. 4, 2009-06 ,pp. : 312-318

Bentham Science Publishers

Access to resources Recommend Favorite